Lurasidone HC1

Phase 3Small molecule

Sumitomo Pharma America, Inc.

Lurasidone HC1 is one of 100 small molecule programs targeting Schizoaffective Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Schizoaffective DisorderActive, not recruiting

Suicidal IdeationActive, not recruiting

SchizophreniaActive, not recruiting

Schizoaffective DisorderPhase 3

Active, not recruiting

Suicidal IdeationPhase 2/Phase 3

Active, not recruiting

SchizophreniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Lurasidone HC1

Sumitomo Pharma America, Inc.

Phase 3

5 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Zocor

OOrganon and Co

Preclinical

6 6

Depakote

Ibrance

Lunesta

3 9

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 10

Luvox

SSolvay Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia5 trials

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT00789698·240 enrolled

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Completed·BBukwang Pharmaceutical·Phase 3·NCT03465787·210 enrolled

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT00641745·629 enrolled

Show 2 more trials

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

Completed·SSumitomo Pharma (Suzhou) Co., Ltd.··NCT04432688·3,192 enrolled

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT00549718·489 enrolled

Interaction3 trials

Midazolam Drug-Drug Interaction Study With Lurasidone HCl

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT01082263·24 enrolled

Rifampin Drug-Drug Interaction Study With Lurasidone HCl

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT01082276·20 enrolled

Lithium Drug-Drug Interaction Study With Lurasidone HCl

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT01074073·24 enrolled

Schizoaffective Disorder2 trials

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT01143090·149 enrolled

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT01143077·244 enrolled

Suicidal Ideation2 trials

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Unknown status·NNeuroRx, Inc.·Phase 3·NCT03396068·72 enrolled

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Completed·NNeuroRx, Inc.·Phase 2/3·NCT03395392·74 enrolled

Tics1 trial

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT01074632·26 enrolled

4 more indications

Depression1 trial

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

Terminated·SSumitomo Pharma (Suzhou) Co., Ltd.·Phase 3·NCT04383691·124 enrolled

Biomarker1 trial

NRX101 Glx Biomarker Validation Study

Completed·NNeuroRx, Inc.·Phase 2/3·NCT03402152·8 enrolled

Pediatric1 trial

Pediatric Open-Label Extension Study

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT01914393·702 enrolled

Unspecified2 trials

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT01082250·52 enrolled

Lurasidone Low-Dose - High-Dose Study Study

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT01821378·412 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Lurasidone HC1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lurasidone HC1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lurasidone HC1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sumitomo Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sumitomo Pharma America, Inc.

Lurasidone HC1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia5 trials

Interaction3 trials

Schizoaffective Disorder2 trials

Suicidal Ideation2 trials

Tics1 trial

Depression1 trial

Biomarker1 trial

Pediatric1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News